Peroxide gel: Efficacy of Hydrogen Peroxide Gel on Periodontitis With Diabetes

Sponsor
University of Oklahoma (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05669560
Collaborator
Perio Protect LLC (Industry)
60
2
53.3

Study Details

Study Description

Brief Summary

Periodontitis is a chronic infectious disease characterized by loss of tooth supporting periodontal structures and alveolar bone. In the U.S. and worldwide, periodontitis is the major cause of tooth loss in adults.

Type 2 Diabetes mellitus (T2DM) is a complex disease that affects 13-15 million Americans and is associated with a variety of serious complications. T2DM is well established as a strong systemic risk factor for periodontitis. The severity and prevalence of periodontitis is much higher in patients with diabetes. This relationship may be bi-directional.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: PerioProtect ™= plastic tray +1.7% hydrogen peroxide
Early Phase 1

Detailed Description

The primary treatment for periodontitis is scaling and root planing (SRP), which refers to the mechanical disruption and removal of bacteria and bacterial toxins from the affected tooth root surfaces. This procedure predictably reduces the bacterial load and produces marked improvement in clinical periodontal parameters, though not always complete resolution of the disease. Periodontal therapy may have some systemic benefits by reducing entry into the systemic circulation of pro inflammatory molecules and bacterial byproducts from the periodontal tissues. Since SRP alone is not always a completely effective treatment especially in advanced stages of periodontitis, a variety of adjunctive antimicrobial therapies such as local delivery of antimicrobial agents into periodontal pockets have been developed and employed to further reduce the bacterial load from periodontal pockets, with mixed results.

A recent innovation in the arena of local delivery antimicrobial agents is the PerioProtect ™ system (Perio Tray® and PerioGel® Perio Protect, St. Louis, MO). This consists of a closely fitting acrylic tray (similar to an athletic mouthguard), which is used to administer 1.7% hydrogen peroxide gel (Perio Gel®, QNT Anderson, Bismarck, ND) deep into the periodontal pocket and retain the gel in place for a sufficient time period (15 minutes) to effectively reduce the periodontal bacterial load. Studies to date have shown that when PerioProtect ™ is used as adjunct to conventional SRP, this system produces additional benefits in reducing the severity of periodontal disease. However, no studies have yet investigated the use of PerioProtect ™ in patients with T2DM and periodontitis.

Based on the concept of a bi-directional relationship of diabetes and periodontitis, the investigators hypothesize that successful management of periodontal infection in diabetics with the use of PerioProtect ™ will not only improve periodontal status, but also result in improved metabolic control of T2DM.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy of Hydrogen Peroxide Gel on Periodontal Ststus and Metabolic Control in Diabetic Patients: a Randomized Control Trial
Anticipated Study Start Date :
Jan 20, 2023
Anticipated Primary Completion Date :
May 30, 2027
Anticipated Study Completion Date :
Jun 30, 2027

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control group

Will receive SRP alone.

Experimental: Test group

Will receive SRP + PerioProtect ™.

Combination Product: PerioProtect ™= plastic tray +1.7% hydrogen peroxide
Subjects will receive PerioProtect ™ in adjunct to mechanical therapy. 15minutes, twice a day, for 3 months.

Outcome Measures

Primary Outcome Measures

  1. Change of HbA1C measured in percentage. [Measured at baseline]

    To investigate the efficacy of locally delivered 1.7% hydrogen peroxide gel (Perio Gel®)as an adjunct to mechanical periodontal therapy on glycemic control in periodontitis patients with Type 2 diabetes mellitus.

  2. Change of HbA1C measured in percentage. [Measured at 3 months]

    To investigate the efficacy of locally delivered 1.7% hydrogen peroxide gel (Perio Gel®)as an adjunct to mechanical periodontal therapy on glycemic control in periodontitis patients with Type 2 diabetes mellitus.

  3. Change of HbA1C measured in percentage. [Measured at 6 months]

    To investigate the efficacy of locally delivered 1.7% hydrogen peroxide gel (Perio Gel®)as an adjunct to mechanical periodontal therapy on glycemic control in periodontitis patients with Type 2 diabetes mellitus.

  4. Change of HbA1C measured in percentage. [Measured at 9 months]

    To investigate the efficacy of locally delivered 1.7% hydrogen peroxide gel (Perio Gel®)as an adjunct to mechanical periodontal therapy on glycemic control in periodontitis patients with Type 2 diabetes mellitus.

Secondary Outcome Measures

  1. Change in Probing Pocket Depth(mm) [Measured at baseline, 3, 6, 9months.]

    To determine if the use of PerioProtect ™ as an adjunct to mechanical therapy produces additional improvement in periodontal status as compared to conventional periodontal therapy (SRP) alone.

  2. Change in Bleeding On Probing(%) [Measured at baseline, 3, 6, 9months.]

    To determine if the use of PerioProtect ™ as an adjunct to mechanical therapy produces additional improvement in periodontal status as compared to conventional periodontal therapy (SRP) alone.

  3. Change in Plaque Index (0-3). [Measured at baseline, 3, 6, 9months.]

    To determine if the use of PerioProtect ™ as an adjunct to mechanical therapy produces additional improvement in periodontal status as compared to conventional periodontal therapy (SRP) alone.

  4. Change in Clinical attachment levels(mm). [Measured at baseline, 3, 6, 9months.]

    To determine if the use of PerioProtect ™ as an adjunct to mechanical therapy produces additional improvement in periodontal status as compared to conventional periodontal therapy (SRP) alone.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Adults >18 , <80 year old with moderate to severe periodontitis as defined by the Word workshop criteria having Type II diabetes mellitus with HbA1 C levels of >6.5%.

  2. No SRP within the past 6 months.

  3. Willingness to comply with study instructions and refrain from using oral hygiene products/ procedures outside the study.

Exclusion Criteria:
  • The researcher believes that it is not in the patient's best interest to stay in the study

  • Based on the exclusion criteria, the patient becomes ineligible to participate

  • Patient's medical condition requires interventions which preclude involvement in the study

  • Patient does not follow study related instructions

  • The study is suspended or canceled

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Oklahoma
  • Perio Protect LLC

Investigators

  • Study Chair: John Dmytryk, DDS, PhD, The University of Oklahoma, College of Dentistry, Division in Periodontics

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jaewon Kim, Clinical Assistant Professor, University of Oklahoma
ClinicalTrials.gov Identifier:
NCT05669560
Other Study ID Numbers:
  • HPOUHSC
First Posted:
Jan 3, 2023
Last Update Posted:
Jan 3, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Jaewon Kim, Clinical Assistant Professor, University of Oklahoma
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 3, 2023